addition, sunitinib stimulated the expression of IL-6 in freshly isolated leukemia cells from AML patients (n ¼ 2), as well as in the peripheral blood mononuclear cells from healthy volunteers (n ¼ 3) (data not shown). Moreover, we found that administration of sunitinib (n ¼ 5, 20 mg/kg, 5 days) to C57BL/6 mice stimulated the expression of IL-6 in their spleen lymphocytes ( Figure 2b ).
We next attempted to verify the molecular mechanisms whereby sunitinib stimulated the expression of IL-6 in Kasumi-1R cells. The transcription factor, c-Jun, binds to the activator protein-1 site of the promoter region of IL-6 gene and intimately regulates its expression. 3 The nuclear levels of c-Jun in Kasumi-1R cells were significantly higher than those in Kasumi-1 cells (Figure 3a) . Chromatin immunoprecipitation assay found that an amount of c-Jun on the IL-6 promoter was greater in Kasumi-1R cells than those in Kasumi-1 cells (Figure 3b ). In addition, exposure of Kasumi-1 cells to sunitinib (100 nM, 48 h) prominently stimulated the binding of c-Jun on the IL-6 promoter ( Figure 3b) .
It is noted that, tocilizumab (20 mg/ml), a humanized anti-IL-6 receptor antibody, or AG490 (5 mM) effectively blocked JAK2/STAT5 signaling (data not shown) and restored the sensitivity of Kasumi-1R cells to sunitinib (Figures 4a and b) , confirming the critical roles of IL-6/JAK2/ STAT5 axis in acquisition of drug-resistant character of Kasumi-1 cells.
Recent studies exploring the effects of the multitargeted tyrosine kinase inhibitor in AML patients harboring the activating mutation in FLT3 found that STAT5 was not efficiently dephosphorylated in some of the patients who did not respond to the inhibitor, although phosphorylation of FLT3 was effectively inhibited in these patients. 4 The multitargeted tyrosine kinase inhibitor could induce the expression of IL-6, leading to the activation of JAK2/STAT5 signaling in these patients. Inhibition of this prosurvival signaling by tocilizumab or the specific inhibitor of JAK2 might improve the clinical outcome of these patients.
BCR/ABL kinase interacts with and phosphorylates the RAD51 paralog, RAD51B BCR/ABL kinase-positive CD34 þ stem/progenitor cells from chronic myeloid leukemia (CML) display elevated levels of DNA double-strand breaks (DSBs) induced by reactive oxygen species (ROS) and various genotoxic agents, including g-radiation.
1 To survive, CML cells repair these numerous DSBs, which generate chromosomal aberrations because BCR/ABL kinase affects the fidelity of repair mechanisms. 1 Thus, CML cells can accumulate additional chromosomal aberrations during the course of disease (ROS dependent) and also in cells surviving bone marrow transplantation (genotoxic agent dependent). The latter statement is supported by the reports that CD34 þ CML stem and progenitor cells are resistant to genotoxic agents. 2 Our earlier studies showed that BCR/ABL kinase interacts with RAD51 resulting in its phosphorylation on Y315, which stimulates repair of DNA lesions by the homologous recombination repair (HRR). 3 HRR is responsible for the repair of about 43% of DSBs in BCR/ABL-transformed cells. 4 RAD51 protein promotes homology search and strand invasion during HRR, which uses an undamaged copy of broken DNA as a template for the repair process. 5 Homologous recombination repair events are also regulated by RAD51 paralogs, RAD51B, RAD51C, RAD51D, XRCC2 and XRCC3. 6 The paralogs can form various complexes in human cells displaying different functions during HRR. For example, RAD51C-XRCC3 and RAD51D-XRCC2 catalyze homologous pairing, and RAD51B-RAD51C is likely required for the assembly of the RAD51-ssDNA nucleoprotein filament. The formation of RAD51 foci after DNA damage is dependent on the paralogs and suggests the existence of functional interactions between these proteins. Cells defective in any of the RAD51 paralogs are sensitive to DNA-damaging agents and to g-radiation.
We have shown previously that in addition to RAD51, expression of RAD51 paralogs may be de-regulated in CMLblast crisis cells, implicating their role in malignant disease progression. 3 For example, RAD51B was upregulated, whereas XRCC3 was downregulated.
Using pull-down assay we found that BCR/ABL interacts with glutathione S-transferase (GST)-RAD51B, but not GST-XRCC3 in a kinase-independent manner (Figure 1a ). This interaction resulted in tyrosine phosphorylation of RAD51B. Phosphorylation of RAD51B was also detected in the in vitro kinase assay in which GST-RAD51B was used as a substrate for the ABL kinase (Figure 1b) . BCR/ABL-RAD51B interaction and RAD51B phosphorylation was also detected in vivo in BCR/ABL-transformed cells, but not in parental cells in which c-ABL kinase activity was not stimulated by DNA damage or cytokines (Figure 1c ). However, it is possible that RAD51B could be phosphorylated also by c-ABL under the conditions stimulating the kinase.
To pinpoint the mechanisms of BCR/ABL-RAD51B interaction, a series of BCR/ABL fragments fused to GST were used (Figure 2a) . Pull-down experiments show that BCR/ABL SH3 domain and BCR B fragment (amino acids 158-633) readily associated with RAD51B, whereas weak association was detected with SH1 (kinase domain) and CT2 fragments ( Figure 2b ). As SH3 domain often involves interaction with proline-rich (PxxP) motif, we mutated the only PxxP motif in RAD51B by introduction of P326L amino-acid substitution; this Figure 1 Interaction and phosphorylation of RAD51B by BCR/ABL kinase. (a) BCR/ABL interacts with and phosphorylates RAD51B in vitro. p210BCR/ABL kinase-active (ka) protein and the kinase-defective (kd) mutant were translated in vitro. Autophosphorylation of BCR/ABL-ka, but not BCR/ABL-kd was confirmed by immunobloting with anti-P.Tyr antibody (not shown). Equal amounts of BCR/ABL-ka and BCR/ABL-kd proteins were incubated with glutathione S-transferase (GST), GST-RAD51, GST-RAD51B and GST-XRCC3 in the kinase buffer in the presence of ATP. The reaction products were separated by SDS-polyacrylamide gel electrophoresis and analyzed by western blotting, using anti-ABL and antiphosphotyrosine (anti-P.Tyr) antibody to detect BCR/ABL (upper panel) and tyrosine phosphorylated (P.Tyr) GST-proteins; GST-proteins were detected by Ponceau red staining (lower panels). (b) ABL kinase phosphorylates RAD51B in vitro. Purified ABL kinase was added ( þ ) or not (À) to the kinase reaction with GST-RAD51B as a substrate. Reaction product was analyzed by western blotting using anti-P.Tyr antibody to detect phosphotyrosine-GST-RAD51B and anti-RAD51B antibody to detect RAD51B. mutation disrupted the interaction of RAD51B with SH3 domain of BCR/ABL (Figure 2c, left panel) . Moreover, P1013L aminoacid substitution in SH3 domain of ABL, which is equivalent to the P131L c-ABL mutant defective in binding to target proteins containing PxxP motifs, 7 abrogated binding to RAD51B (Figure 2c, right panel) . Thus, this combined effort identified the SH3 domain of BCR/ABL and PxxP motif of RAD51B as the site of interaction between the BCR/ABL oncogenic protein and RAD51B DNA repair protein.
Tyrosine 177 (Y177) present in BCR fragment B represents another key element in BCR/ABL-mediated leukemogenesis. 8 Phosphorylation-less Y177F amino-acid substitution in the BCR B fragment abrogated the binding of RAD51B (Figure 2d) , providing an exciting possibility that BCR/ABL-associated adaptor proteins can promote the interaction of DNA-repair protein RAD51B with RAS and PI-3k signaling pathways. In fact, immunoprecipitation experiments indicated that Grb2, Shc and CrkL, but not c-Cbl and Gab2 (all members of BCR/ABL proteome), interact with RAD51B (Figure 2e) .
These results indicate that BCR/ABL kinase interacts with and phosphorylates not only RAD51, but also its paralog, RAD51B. BCR/ABL-RAD51B interaction may involve direct contact between the SH3 domain of BCR/ABL and the proline-rich region of RAD51B and also indirect contact in which adaptor proteins (for example, Grb2) associate RAD51B with phospho-Y177 of BCR/ABL. We hypothesize that BCR/ABL-mediated tyrosine phosphorylation of RAD51 3 and RAD51B (this report) may affect the interaction between the paralogs to enhance the efficiency and/or diminish the fidelity of HRR in CML. It is also plausible that c-ABL kinase activated by DNA damage can interact and phosphorylate not only RAD51 but also RAD51B to regulate HRR in normal cells. 9 
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